Damora Therapeutics (DMRA) stock
DMRA's Quality Score fell 3 points on Fri, Nov 20, to -1. Buying slipped from its highest in 20 days (3 chart checks stopped).
New listing, trading since Mar 10, 2026. 179 trading days so far, so 1 of the 14 chart checks waits for more history.
Follow DMRA's trial news. Pro members can get an alert when Damora Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on DMRA
| Holding it back | A $292M loss |
| Latest filing | 10-Q, Nov 4 |
What's next
Mon Nov 30: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
DMRA catalysts
After its last report it closed -4.7%.
What's next for DMRA, and how long its cash lasts
Its trials
Cash runway
$528M in cash
Dilution on the horizon
- Shelf registration (S-3ASR, filed Feb 10, 2026)
- At-the-market share sales program (S-3ASR, filed Feb 10, 2026)
Insiders
CEO Jennifer Jarrett bought 12,500 shares on Sep 25. 4 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why DMRA scores -1
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- −1Profit A loss of $292M over the last four quarters, more than the $16M lost a year earlier, from the SEC filings
- Volatility subtracts
- Cash flow subtracts
How DMRA ranks in Biotech
DMRA is #110 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 110 |
When does DMRA report earnings, and what happens after?
Expected to report Thu Mar 18, after the close (in 117 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Close after the report, last 1
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +0.9% | -4.7% | +1.4% |
DMRA has 2 of 14 chart checks firing
DMRA RSI on Nov 20: 54.1, above its 50-day average
RSI 54.1, MACD above signal. Not scored.
The deep dive on DMRA
- What it does and how it makes money
- Where it standsSEC filing · Feb 11, 2026
- Who holds and trades it
DMRA insider trades
One insider bought $253K across 1 filing, and one insider sold $7K across 1 filing, in the last 6 months. The newest:
DMRA's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Damora Therapeutics
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn DMRA's score around: 6 things
- 3 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does DMRA's Quality Score say?
DMRA scores -1 today, which Breakaway calls Poor. It is #110 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Shares: 46.6 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is DMRA's Quality Score?
DMRA scores -1 today, which Breakaway calls Poor (below zero). That is #110 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DMRA's -1.
Are insiders buying DMRA?
One insider bought $253K across 1 filing, and one insider sold $7K across 1 filing, in the last 6 months. The newest is Jennifer Jarrett, Director, President and CEO, who bought $253K on Sep 25. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.